Publicaciones en VIVO

Mapa de la ciencia

Red de Coinvestigador

GARCIA ABELLAN, JAVIER

Person (Active)

Positions

Profesor/a Asociado/a en CC. Salud, Medicina Clínica 2021 -

Publications
Research
Teaching
Contact
Otro
Ver todos

supported publications or other works

ANÁLISIS DE LA SATISFACCIÓN Y CALIDAD DE VIDA EN PACIENTES CON VIH EN TRATAMIENTO CON CABOTEGRAVIR-RILPIVIRINA DE ACCIÓN PROLONGADA. REVISIÓN SISTEMÁTICA. TFG
EPIDEMIOLOGÍA DE LAS INFECCIONES BACTERIANAS Y VALOR DIAGNÓSTICO DE LA PROCALCITONINA EN PACIENTES CON INFECCIÓN POR SARS-COV-2 GRAVE. TFM
EVALUACIÓN DEL EFECTO DEL LONG-COVID EN EL GRADO DE ACTIVIDAD FÍSICA Y FRAGILIDAD DE LOS PACIENTES TRAS INFECCIÓN GRAVE POR SARS-COV-2 TFG
IMPACTO DEL USO GENERALIZADO DE ANTIBIÓTICOS DURANTE LA PANDEMIA POR SARS-COV2 TFM
PRINCIPALES CÁNCERES EN PACIENTES CON VIH TFM

selected publications

academic article
- Distinct gut microbiota signatures associated with progression of atherosclerosis in people living with HIV. JOURNAL OF INFECTIOUS DISEASES. 2024
- Early Detection of Cancer and Precancerous Lesions in Persons with HIV through a Comprehensive Cancer Screening Protocol. CLINICAL INFECTIOUS DISEASES. 2024
- Long COVID across SARS-CoV-2 variants, lineages, and sublineages. ISCIENCE. 2024
- No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024
- Virological History Predicts Non-sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Therapy, independent of Pharmacokinetic Parameters. CLINICAL INFECTIOUS DISEASES. 20-40. 2024
- Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study. . CLINICAL INFECTIOUS DISEASES. 2023
- Integrating SARS-CoV-2-specific interferon-¿ release assay testing in the evaluation of patients hospitalized with COVID-19. MICROBIOLOGY SPECTRUM. 2023
- T-Cell Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Measured by an Interferon-¿ Release Assay Is Strongly Associated With Patient Outcomes in Vaccinated Persons Hospitalized With Delta or Omicron Variants . JOURNAL OF INFECTIOUS DISEASES. 2023
- Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-¿ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination. CLINICAL INFECTIOUS DISEASES. 338-346. 2022
- Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study. CLINICAL INFECTIOUS DISEASES. 2022
- Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. FRONTIERS IN IMMUNOLOGY. 2022
- Pericarditis caused by Mycobacterium africanum: case repor. BMC INFECTIOUS DISEASES. 2022
- Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.. EBIOMEDICINE. 2022
- Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral and low-grade systemic inflammation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2257-2264. 2022
chapter
- Actualización en el tratamiento de la infección VIH.Parte I: nuevas moléculas y alternativas terapéuticas en terapia de inicio.. VIH&TARNovedades 2022. 125-147. 2022
congress communication
- Switching to long acting intramuscular cabotegravir and rilpivirine in virologically suppressed PLHIV treated with dolutegravir/rilpivirine. A substudy from the RELATIVITY cohort 2024
thesis
- EVOLUCIÓN CLÍNICA, VIROLÓGICA E INMUNOLÓGICA A LARGO PLAZO DE LOS PACIENTES CON INFECCIÓN GRAVE POR SARS-COV-2: FACTORES PREDICTORES DE COVID PERSISTENTE 2022